Bio Green Med Solution (BGMS) AI Stock Analysis

• Market Cap: $13.48M
• Dividend Yield: 2.86%
• Average Volume (3M): 178.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: -87.50%
• EPS Growth: 92.82%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.98
• Shares Outstanding: 2,238,984
• 10 Day Avg. Volume: 133,386
• 30 Day Avg. Volume: 178,687
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

Bio Green Med Solution Business Overview & Revenue Model

Company Description

A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.

How the Company Makes Money

Cyclacel Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company’s revenue model is centered around licensing agreements, collaborations, and strategic partnerships with other pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on sales of successfully developed products. Additionally, Cyclacel may receive funding from government grants and research collaborations, which support their clinical trials and research initiatives. As a clinical-stage company, significant revenue generation typically occurs post-commercialization of their drug candidates.

Bio Green Med Solution Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Bio Green Med Solution Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: ―
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 7.28, equal to the 50-day MA of 8.56, and equal to the 200-day MA of 49.05, indicating a bearish trend. The MACD of -0.85 indicates Positive momentum. The RSI at 31.51 is Neutral, neither overbought nor oversold. The STOCH value of 8.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.

Bio Green Med Solution Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVTX	60 Neutral	$140.14M	―	-90.25%	―	-45.35%	96.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KPTI	49 Neutral	$54.28M	―	41.08%	―	-5.77%	-22.78%
IMA	41 Neutral	$102.20M	―	-23.76%	―	-100.00%	55.32%
APLT	39 Underperform	$60.57M	―	-150.82%	―	―	―
BGMS	38 Underperform	$13.48M	―	-276.72%	2.86%	-87.50%	92.82%
PRLD	35 Underperform	$63.95M	―	-96.33%	―	―	7.72%

Bio Green Med Solution Corporate Events

Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift

On March 31, 2025, Cyclacel Pharmaceuticals announced the delayed resignation of its co-principal financial officer, David Lazar, and two independent directors, Avraham Ben-Tzvi and David Natan, until the filing of the company’s annual report. Subsequently, on April 2, 2025, the company appointed two new independent directors, Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, to its board. The company also reported financial results for the fourth quarter, highlighting a strategic focus on developing plogosertib, a PLK1 inhibitor for advanced cancers, and the liquidation of its subsidiary, Cyclacel Limited, which is expected to reduce research and development expenses and increase stockholders’ equity by approximately $5 million.

Cyclacel Pharmaceuticals Announces New Leadership and Restructuring

On February 26, 2025, Cyclacel Pharmaceuticals announced a significant change in control and leadership following the completion of a Securities Purchase Agreement. Datuk Dr. Doris Wong Sing Ee acquired a controlling interest in Cyclacel, becoming the new CEO and Executive Director, while Kiu Cu Seng was appointed as the Chief Financial Officer. This transition marks a strategic shift for Cyclacel, potentially impacting its operations and market positioning. The company also experienced several board resignations and new appointments, indicating a broader restructuring effort.